Работы, цитирующие эту работу

Работ: 2

Работа: MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

1. NLRP3 inflammasome-based therapies by natural products: a new development in the context of cancer therapy

   Hamza Abu Owida, Ahmed Abed, Farag M. A. Altalbawy +7

   Обзорная статьяInflammasome and immune disordersNaunyn-Schmiedeberg s Archives of Pharmacology2025Цитирований: 1

   ABIABI:AkademIndex/openalex/2025.review-article.000073

2. Dihydromyricetin: A potential candidate for the treatment of cholestatic liver injury via inhibition of the NLRP3 inflammasome

   Hao Zhang, Yiping Dang, Yuanjin Guo +8

   СтатьяMedicinal plant effects and applicationsEuropean Journal of Pharmacology2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.015269